Oppenheimer Asset Management Inc. Raises Position in Glaukos Corporation $GKOS

Oppenheimer Asset Management Inc. raised its position in Glaukos Corporation (NYSE:GKOS) by 245.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,297 shares of the medical instruments supplier’s stock after buying an additional 10,160 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Glaukos were worth $1,477,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GKOS. Bessemer Group Inc. boosted its stake in shares of Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 158 shares during the last quarter. Nuveen LLC purchased a new position in Glaukos in the 1st quarter valued at $31,474,000. Ehrlich Financial Group acquired a new stake in Glaukos during the 2nd quarter worth $1,034,000. Royal Bank of Canada grew its holdings in shares of Glaukos by 103.2% during the first quarter. Royal Bank of Canada now owns 228,249 shares of the medical instruments supplier’s stock worth $22,464,000 after buying an additional 115,939 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Glaukos in the first quarter valued at about $307,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Trading Up 14.4%

GKOS opened at $88.21 on Friday. The stock has a market capitalization of $5.06 billion, a PE ratio of -57.28 and a beta of 0.76. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The business’s 50 day moving average price is $85.55 and its 200 day moving average price is $91.57.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The company had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share. The company’s revenue for the quarter was up 38.1% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on GKOS shares. Mizuho set a $130.00 price target on shares of Glaukos in a research report on Thursday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. Citigroup increased their price target on Glaukos from $110.00 to $113.00 and gave the company a “buy” rating in a report on Thursday. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.62.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.